Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Pluristem Therapeutics -- Ignore unavailable to you. Want to Upgrade?

To: manny t who wrote (19)	2/8/2007 8:40:40 AM
From: xcentral1	Respond to of 295

LOLOL .... don't know - but word up it IS 2007!!

To: manny t who wrote (19)	2/14/2007 9:10:20 AM
From: xcentral1	Read Replies (1) \| Respond to of 295

Pluristem Announces Private Equity Investment of $8M NEW YORK, Feb 14, 2007 (BUSINESS WIRE) -- Pluristem Life Systems, Inc. (OTCBB:PLRS), a cell therapy Company dedicated to the commercialization of stem cell products for a variety of indications, today announced that it has signed a binding term sheet with new investors for a private equity investment in the amount of $8,000,000. The first payment of funds totaling $1,250,000 has been received. The investors will receive Pluristem restricted common stock at a price of $0.0125 per share and a warrant to purchase additional shares at an exercise price of $0.025 per share. The final agreement is expected to be completed by March 15, 2007. Mr. Zami Aberman, CEO of Pluristem Life Systems stated: "We are delighted these new investors have shown their confidence in Pluristem. Our business strategy targets a potential $30 billion market by capitalizing on our proprietary PLacenta eXpanded (PLX I) and 3D PluriX(TM) technologies and our unique business model of "supply-on-demand" cells for a variety of clinical indications. This financing enables us to fund our activities for the next 2 years and generate the clinical data we believe will support the therapeutic effects of PLX-I in the treatment of hematological malignancies. In addition, we will explore the use of PLX-I in new clinical applications." Pluristem developed PLX I as an allogeneic product, based on supplementing the umbilical cord blood cells with supportive cells that improve the effectiveness of engraftments and shorten recovery times. PLX I mesenchymal stem cells were proven to increase the umbilical cord blood stem cells effectiveness by 3-5 times in a pre-clinical study.